5 Works

Early Itch Response with Abrocitinib is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE 3 COMPARE Trial

Adis Journals on behalf of:, Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, Michael C. Cameron, Ricardo Rojo Cella, Hernan Valdez, Marco DiBonaventura & Claire Feeney
Article full text The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022

Additional file 6 of Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Pei Zhang, Yang Du, Hua Bai, Zhijie Wang, Jianchun Duan, Xin Wang, Jia Zhong, Rui Wan, Jiachen Xu, Xiran He, Di Wang, Kailun Fei, Ruofei Yu, Jie Tian & Jie Wang
Additional file 6. The original blots.

Early Itch Response with Abrocitinib is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE 3 COMPARE Trial

Adis Journals on behalf of:, Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, Michael C. Cameron, Ricardo Rojo Cella, Hernan Valdez, Marco DiBonaventura & Claire Feeney
Article full text The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022

Additional file 6 of Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Pei Zhang, Yang Du, Hua Bai, Zhijie Wang, Jianchun Duan, Xin Wang, Jia Zhong, Rui Wan, Jiachen Xu, Xiran He, Di Wang, Kailun Fei, Ruofei Yu, Jie Tian & Jie Wang
Additional file 6. The original blots.

Early Itch Response with Abrocitinib is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE 3 COMPARE Trial

Adis Journals on behalf of:, Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, Michael C. Cameron, Ricardo Rojo Cella, Hernan Valdez, Marco DiBonaventura & Claire Feeney
Article full text The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022

Registration Year

  • 2022
    5

Resource Types

  • Audiovisual
    5

Affiliations

  • Sun Yat-sen University
    5
  • West China Hospital of Sichuan University
    5
  • Northwest Normal University
    5
  • Fudan University
    5
  • Shanghai Jiao Tong University
    5
  • Anhui Agricultural University
    5
  • Sichuan Agricultural University
    5
  • Renmin Hospital of Wuhan University
    5
  • Harvard University
    5
  • Zhejiang Chinese Medical University
    4